https://www.acumenresearchandconsulting.com/
Home Services Industry Services Press Releases About Us Blogs Report Store Contact us

Oral HIV Treatment Market (By Drug Class : Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Multi-Class Combination Therapies, Protease Inhibitors (PIs), Entry and Fusion Inhibitors, and Co-receptor Antagonists) - Global Industry Analysis, Market Size, Opportunities And Forecast 2020 - 2027

Published : Mar 2021

Report ID: ARC2470

Pages : 190

Format : Oral HIV Treatment Market (By Drug Class : Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Multi-Class Combination Therapies, Protease Inhibitors (PIs), Entry and Fusion Inhibitors, and Co-receptor Antagonists) - Global Industry Analysis, Market Size, Opportunities And Forecast 2020 - 2027

CHAPTER 1. Industry Overview of Oral HIV Treatment
1.1. Definition and Scope
1.1.1. Definition of Oral HIV Treatment
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Oral HIV Treatment Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Oral HIV Treatment Market By Drug Class
1.2.3. Oral HIV Treatment Market by Regions

CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources

CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restrain 1
3.2.2. Restrain 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Oral HIV Treatment Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Oral HIV Treatment Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Cost Structure Analysis
3.8.1. Price Trend of Key Raw Materials
3.8.2. Raw Material Suppliers
3.8.3. Proportion of Manufacturing Cost Structure
3.8.3.1. Raw Material
3.8.3.2. Labor Cost
3.8.3.3. Manufacturing Expense
3.9. Regulatory Compliance
3.10. Competitive Landscape, 2019
3.10.1. Player Positioning Analysis
3.10.2. Key Strategies Adopted By Leading Players

CHAPTER 4. Manufacturing Plant Analysis
4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2019
4.2. R&D Status and Application Source of Oral HIV Treatment Major Manufacturers in 2019

CHAPTER 5. Oral HIV Treatment Market By Drug Class
5.1. Introduction
5.2. Oral HIV Treatment Revenue By Drug Class
5.2.1. Oral HIV Treatment Revenue (US$ Mn) and Forecast, By Drug Class, 2016-2027
5.2.2. Nucleoside-analog reverse transcriptase inhibitors (NRTIs)
5.2.2.1. Nucleoside-analog reverse transcriptase inhibitors (NRTIs) Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
5.2.3.1. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Market Revenue (US$ Mn) and Growth Rate (%) 2016-2027
5.2.4. Multi-class combination therapies
5.2.4.1. Multi-class combination therapies Market Revenue (US$ Mn) and Growth Rate (%) 2016-2027
5.2.5. Protease inhibitors (PIs)
5.2.5.1. Protease inhibitors (PIs) Market Revenue (US$ Mn) and Growth Rate (%) 2016-2027
5.2.6. Entry and Fusion Inhibitors
5.2.6.1. Entry and Fusion Inhibitors Market Revenue (US$ Mn) and Growth Rate (%) 2016-2027
5.2.7. Co-receptor Antagonists
5.2.7.1. Co-receptor Antagonists Market Revenue (US$ Mn) and Growth Rate (%) 2016-2027

CHAPTER 6. North America Oral HIV Treatment Market By Country
6.1. North America Oral HIV Treatment Overview
6.2. U.S.
6.2.1. U.S. Oral HIV Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
6.3. Canada
6.3.1. Canada Oral HIV Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
6.4. North America PEST Analysis

CHAPTER 7. Europe Oral HIV Treatment Market By Country
7.1. Europe Oral HIV Treatment Market Overview
7.2. U.K.
7.2.1. U.K. Oral HIV Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
7.3. Germany
7.3.1. Germany Oral HIV Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
7.4. France
7.4.1. France Oral HIV Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
7.5. Spain
7.5.1. Spain Oral HIV Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
7.6. Rest of Europe
7.6.1. Rest of Europe Oral HIV Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
7.7. Europe PEST Analysis

CHAPTER 8. Asia Pacific Oral HIV Treatment Market By Country
8.1. Asia Pacific Oral HIV Treatment Market Overview
8.2. China
8.2.1. China Oral HIV Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
8.3. Japan
8.3.1. Japan Oral HIV Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
8.4. India
8.4.1. India Oral HIV Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
8.5. Australia
8.5.1. Australia Oral HIV Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
8.6. South Korea
8.6.1. South Korea Oral HIV Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
8.7. Rest of Asia-Pacific
8.7.1. Rest of Asia-Pacific Oral HIV Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
8.8. Asia Pacific PEST Analysis

CHAPTER 9. Latin America Oral HIV Treatment Market By Country
9.1. Latin America Oral HIV Treatment Market Overview
9.2. Brazil
9.2.1. Brazil Oral HIV Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
9.3. Mexico
9.3.1. Mexico Oral HIV Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
9.4. Rest of Latin America
9.4.1. Rest of Latin America Oral HIV Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027

CHAPTER 10. Middle East & Africa Oral HIV Treatment Market By Country
10.1. Middle East & Africa Oral HIV Treatment Market Overview
10.2. Saudi Arabia
10.2.1. Saudi Arabia Oral HIV Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
10.3. UAE
10.3.1. UAE Oral HIV Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
10.4. Rest of Middle East & Africa
10.4.1. Rest of Middle East & Africa Oral HIV Treatment Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027

CHAPTER 11. Player Analysis of Oral HIV Treatment
11.1. Oral HIV Treatment Market Company Share Analysis
11.2. Competition Matrix
11.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
11.2.2. New Product Launches and Product Enhancements
11.2.3. Mergers And Acquisition In Global Oral HIV Treatment Market
11.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements

CHAPTER 12. Company Profile
12.1. Cipla Limited
12.1.1. Company Snapshot
12.1.2. Business Overview
12.1.3. Financial Overview
12.1.3.1. Revenue (US$ Mn), 2019
12.1.3.2. Cipla Limited 2019 Oral HIV Treatment Business Regional Distribution
12.1.4. Product/ Service and Specification
12.1.5. Recent Developments & Business Strategy
12.1.6. Manufacturing Plant Footprint Analysis
12.2. AbbVie Inc.
12.3. Gilead Sciences, Inc.
12.4. Boehringer Ingelheim International GmbH
12.5. Merck & Co., Inc.
12.6. Pfizer Inc.
12.7. GlaxoSmithKline plc.
12.8. Johnson & Johnson
12.9. F. Hoffmann-La Roche Ltd.
12.10. Teva Pharmaceutical Industries Ltd
12.11. Others

Frequently Asked Questions

What will be the market value of the oral HIV treatment market?

Oral HIV treatment market is expected to reach a market value of around US$ 2,944.5 Mn by 2027.

At what CAGR, the oral HIV treatment is expected to grow during the forecast period (2020-2027)?

The oral HIV treatment market is expected to grow at a CAGR of around 4.1% from 2020 to 2027.

Which is the leading segment in the oral HIV treatment?

Drug class segment is the leading segment in the overall market.

What are the key drivers of the oral HIV treatment?

Combination therapy is one of the prominent factors that drive the demand for oral HIV treatment market.

Which are the prominent players in the oral HIV treatment market?

Cipla Limited, AbbVie Inc., Gilead Sciences, Inc., Boehringer Ingelheim International GmbH, Merck & Co., Inc., Pfizer Inc., GlaxoSmithKline plc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., and among others.

Which region held the highest market share in the oral HIV treatment market?

North America is anticipated to grab the highest market share in the regional market

Which region is expected to be the fastest growing market over the forecast period?

Asia Pacific is expected to be the fastest growing market in the forthcoming years

Select Licence Type

Single User

US$ 4500

Multi User

US$ 7000

Excel Datapack

US$ 2000

Why Acumen Research And Consulting

100%

Customer Satisfaction

24x7

Availability - we are always there when you need us

200+

Fortune 50 Companies trust Acumen Research and Consulting

80%

of our reports are exclusive and first in the industry

100%

more data and analysis

1000+

reports published till date